ESMO 2026: Surgery in high-risk localised prostate cancer

Share :
Published: 26 Oct 2026
Views: 1356
Rating:
Save
Prof Bertrand Tombal, Prof Thomas Steuber, Prof Gert Attard and Dr Mary-Ellen Taplin

Prof Bertrand Tombal (Université Catholique de Louvain, Brussels, Belgium), Prof Thomas Steuber (University Medical Center Hamburg-Eppendorf, Hamburg, Germany), Prof Gert Attard (University College London Cancer Institute, UK) and Dr Mary-Ellen Taplin (Dana-Farber Cancer Institute, Boston, USA) discuss recent changes in the management of high-risk localised prostate cancer, with a focus on the role of surgery and how emerging clinical trial data may influence treatment decisions.

The panel reviews findings from the PROTEUS and STAMPEDE trials, alongside the DASL-HiCaP study, and discusses treatment options including radical prostatectomy, radiotherapy, androgen deprivation therapy (ADT), and androgen receptor pathway inhibitors such as apalutamide, darolutamide and abiraterone.

The experts consider the benefits of treatment intensification, the potential need for multimodal approaches and how to select the most appropriate local treatment for individual patients.

The discussion also explores patient risk stratification using PSMA PET imaging and molecular classifiers, which may help identify patients most likely to benefit from treatment intensification and those who could avoid unnecessary treatment.

The panel considers the challenges of applying clinical trial findings to different risk groups, balancing treatment efficacy with side effects, and choosing therapies based on patient preferences, tolerability, cost and availability.

Perioperative apalutamide (APA) plus androgen-deprivation therapy (ADT) with radical prostatectomy plus pelvic lymph node dissection (RP + PLND) vs RP + PLND alone in patients (pts) with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): PROTEUS substudy
Darolutamide with androgen deprivation therapy (ADT) and definitive or salvage locoregional radiation therapy (RT) for localised, very high-risk prostate cancer: interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)
How to choose treatment for locally advanced prostate cancer
AI-based prediction of metastasis-free survival using MRI-derived radiomics for risk stratification in localized prostate cancer

 

Supported by an independent educational grant from Johnson & Johnson

BT: Hello everybody, I'm Bertrand Tombal, a urologist from Brussels, Belgium, and we are here to discuss the management of high-risk localised prostate cancer. Once again, in the last six months, dramatic changes, and we're going to discuss what are the changes, do they apply to everybody, and what can we do. For this, I have the privilege of being here with a panel of many distinguished colleagues that I'm going to ask that they introduce themselves.

MT: Hello, I'm Dr. Mary Ellen Taplin. I'm a professor of medicine at Harvard Medical School in Boston, Massachusetts, and a GU medical oncologist at the Dana-Farber Cancer Institute. Gert Hathard.

GA: Gerhardt Attard, I'm a medical oncologist in London, UK, University College London.

TS: My name is Thomas Steuber. I'm a urologist working at the Martini Clinic Prostate Cancer Centre in Hamburg, Germany.

BT: So thank you all. So, I mean, first part would be to briefly summarise what has been presented here. I mean, the surgical part, which is clearly PROTEUS, you are the PI. This was a sub-study to clearly understand what was the benefit of ADT plus apalutamide together or nothing.

MT: So the proteus sub-study was presented at ESMO, and this study is a 400-patient trial in which in a three-to-one fashion, patients went either sent straight to prostatectomy or received the PROTEUS regimen, which was six months of ADT and apalutamide before and after prostatectomy. Primary endpoint was event-free survival.

BT: And then the DASL?

TS: Yeah, the DASL-HiCaP was actually a similar population. It's a high-risk population, localised or locally advanced, non-metastatic. And there were more than 1,100 patients randomised one-to-one in the standard of care arm, which is radiation plus two years of ADT versus radiation plus two years of ADT plus an RP, which is darolutamide in this setting.

BT: And when we look at the result, I mean, in both cases, the endpoints are met. For PROTEUS, there were a few discussion about the definition of the endpoint. It was mostly PSA, PSMA-based, where in DASL, it's MFS, conventional MFS. So what can we see about this endpoint and how they've been hitted?

MT: Yeah, the PROTEUS endpoint was a three-year endpoint, so the primary endpoint was event-free survival. And as you noted, Bertrand, most of the relapses were PSA relapse and local relapses. A key secondary endpoint was MFS by conventional or PSMA PET imaging, although most of the events that were reached were PSMA PET. Both were positive with very strong hazard ratios.

BT: And for DASL?

TS: Yeah, for DASL, it was like they were looking at the four-year metastasis-free survival rates based on conventional imaging, so they did not use the PSMA PET scan and saw a significant advantage in favour of the addition of an RP of darolutamide, yeah, to reduce the risk of distant metastasis at conventional imaging.

BT: So we have here two trials in high-risk patients, and we were discussing before, it's true if you look at the…it's not the placebo, the surgery arm, I mean, it's only 30% of the patients are event-free at three years. So it means that when we first look…when I first look at the patient population, it looked to me there were many patients that were not that high-risk, but here, it tend to prove the opposite, that for some reason, they were well-selected to be a very high-risk.

MT: Yeah, we intentionally made the eligibility to be weighted towards high-volume high-risk, so the vast majority of the patients were Gleason 8, 9, and 10. In fact, all of them were 8, 9, and 10, and then you had to have six core biopsies if you were an 8 and fewer if you were a 9 or a 10. So they were very high-risk, and as you noted, only 30% in the prostatectomy arm at three years hadn't relapsed or maybe more subsequently relapsed, so they're very high-risk.

BT: And then DASL, it was also like Gleason 9 and 10, Gleason 8 with significant features, CN1 on conventional imaging. So we are really at the high end of the high-risk. I mean, we're very close to one PSMA step of being metastatic and diagnostic because it's this in-between. And that's my question and my worry is that how can we extrapolate that to a patient that would be at less risk, and that when you, where you come in, how can we better select the patient that needs some form of intensification minimum or even in the future ADT? So what can we do for this patient?

GA: So at STAMPEDE, we have 12, 14 years follow-up, and we can see even with that duration of follow-up, about 20% will die from prostate cancer, and about an additional 20% will have metastasis by conventional imaging but have not died yet. That means about half of patients may be in remission, and that's with ADT and radiotherapy. And the risk is similar. So in STAMPEDE, there's a few more, a higher proportion of node-positive versus DASL-HiCaP, but DASL-HiCaP has a higher proportion of Gleason 910, which is an interesting risk factor in its own that they have defined. So there is, we should be using these treatments, that's my conviction based on two positive trials now with MFSCI and PROTEUS with an EFS endpoint, but we are likely to over-treat and just based on clinical factors. I think there are two approaches around that. The first is imaging, PSMA PET, and over the next few years we'll learn better who to select based on PSMA PET, and the second is molecular biomarkers. And that's one question we've been able to test in STAMPEDE, and that can also be tested in ENZARAD, hopefully in protease as well. I hope in DASL-HiCaP, I suspect as well. And at this meeting, we presented data on transcriptome profiling. There's a number of mRNA classifiers or signatures we can extract, but the one we focused on is the one with the most data across both earlier risk patients and this very high-risk group, which is Decipher, which many of the listeners will know about or have used in the localised, earlier localised setting.

And there's a, even in STAMPEDE very high-risk patients, about a third of patients are in a low-risk group by Decipher score, and that group have a very low risk of distant metastasis even after 10 or 12 years. So this introduces the hypothesis that we could spare them treatment. Similarly, across NCCN high-risk, and that's the population that was randomised in ENZARAD but showed no MFS benefits.

So we can't treat all NCCN high-risk, but we want to look for high-risk patients within that group, and about 30% in the NCCN high-risk, excluding the very high-risk, have a high Decipher score. They have rates of distant metastasis in a real-world dataset we exploited that are similar to the STAMPEDE very high-risk population. So this is hypothesis generating, but potentially we could avoid intensification for patients found to be lower risk or have high-risk clinical features, and conversely, we could identify NCCN high-risk patients to the left of the very high-risk, but we could intensify.

The question I don't have the answer to is how do we convince the community and payers without a new prospective trial, and there are a few prospective trials, so that may be the answer. But at least in the interim, we are, as we've just said, we have the opportunity to analyse tumours from across our large trials.

BT: I would then, you know, I'm an aficionado of a randomised controlled trial, but if we have three, four very well-conducted randomised controlled trials who show the same direction, I would be keen to say that we should avoid over-treatment and over-expense, because the question is always what do you do awaiting the result of this trial. Here in Belgium, we have the THUNDER trial, where patients are selected based on a decipher and PSMA, it's  trial. Those who are PSMA negative and decipher low, they receive darolutamide monotherapy, the other one are randomised. So I think really when we're going to have to go to speak to payer, we're going to have to come with something to reassure them.

And then there is the question, okay, which how do we choose a local treatment in that subgroup of patients? I was making fun of Declan Murphy when he discussed your brilliant presentation. I say, I'm going to buy you a hat and say, make prostatectomy great again, okay? So well, I mean, you from Hamburg, I mean, you guys have largest experience in Europe at the present time in radical prostatectomy. What do we have to tell our colleague urologists? Is there a upper limit? And most importantly, is there a patient that can still in the high-risk group? And that was my question to Alberto, that could benefit just simply from prostatectomy, because that's an important question.

TS: I mean, distinguishing between radiation or radical prostatectomy, I mean, we hear the debates on experts, we see the debates on APCCC, and it's kind of a fight, but it's of course, you have to have good arguments. But I think we can say that no prospector-randomised trial showing the superiority of one over the other treatment modalities. Not every candidate is suitable for radiation, not everybody is suitable for surgery.

Patients have a notion, have an idea, they have a preference, and of course, if we sell or if we recommend a treatment option, we have to be honest and say, probably it comes in a multimodal approach. So surgery alone is most likely not enough, based on final histopathology and additional radiation plus ADT, which is the standard of care right now, maybe supplemented. Likewise, radiation comes with ADT, or in the very high-risk setting, already established abiraterone, based on the M0 STAMPEDE.

So I think balancing side effects and organisation of the treatment, this is the first thing we need to discuss with our patients. And of course, we have the randomised trial from the Swedish group running, SPCG15, comparing radiation plus radical prostatectomy. Will be very interesting to see whether there's a superiority of one over the other.

On the other hand side, once we have these results, the addition of an RP, for example, which may be considered standard of care, but we have these results, has not been introduced in this trial. So we're far away.

BT: As regards to this, a very interesting observation in PROTEUS is that, at least at the three-year landmark, you reduce the rate of salvage radiation therapy. Because I mean, to me, whether it's surgery or radiotherapy, the second one is not very good. I mean, surgery after radiotherapy or vice versa. So that's a nice observation in PROTEUS, that you significantly reduce the rate of salvage radiotherapy, no?

MT: Yeah, it was reduced by 50%, and either adjuvantly or in the salvage setting. And I think that's important for patients. I call it double local therapy with the surgery and the radiation. And it might be a trade-off of a year of androgen deprivation therapy with surgery, as opposed to starting the surgery alone and followed up by salvage hormones and radiation.

So I believe you have to talk to the patients and individualise each of the three modalities, surgery, radiation, and the androgen deprivation, with or without an androgen pathway inhibitor, and try to figure out with the patient what might be best for him.

BT: And then the last question, tomorrow we've got darolutamide approved in the setting, still that's not a limitation because it's due to time. It was not a Daro versus Abi trial in the N1, so we can live with that. It's not a problem. But how are you going to choose between an amide and Abbey? I mean, because you have a huge experience with Abi over a long period of time. In that setting, two years, STAMPEDE hasn't shown dramatic signals. So how are we going to make that choice?

GA: So if cost is a consideration, for now, Abi will win hands down. And there are many health care systems where cost is a consideration, so I think Abi will continue to be used. If cost is not a consideration, I think Darolutamide is probably better tolerated, and that will be factored into the decision-making process. There's still many countries here in Europe and elsewhere where abiraterone is not available because the licencing, the licence has not been extended, so the payers or the regulators may not allow its use. And I would suspect Bayer, or I hope Bayer, will go on to make Darolutamide available. So that's a new population of patients who have no access to Abi who will have access to Darolutamide.

BT: And then a urologist to urologist question. You know, we did participate to the trial, you know, 15 years ago, and there was always that kind of a warning that, be careful, six months of profound androgen deprivation therapy will induce some, I still remember my boss saying, desmoplastic reaction. What's your experience? It's not more complicated to do a prostatectomy?

TS: Not at all. I mean, we have randomised data now. The INDUCTA trial, it was an IIT from Germany. So they looked at clinical T3 to 4, so patients that are too advanced for surgery.

So they did an inductive treatment with apalutamide ADT, and it turned out that 20 out of 20 patients were downsized and then suitable for surgery with good results and no complications. So in my experience, this is, this doesn't hold true that a previous neoadjuvant androgen deprivation or intensified androgen deprivation harms the surgery. Not at all.

BT: Okay. I think that's a very important message because this is something, I mean, it shouldn't be a, it shouldn't be a reason. And then for you, the last one, why do you need to give six months after surgery when they have PT0?

MT: Yeah. That's a great question that should be explored. And we only have the data of the way the trial was designed with six months before and six months after. But I think it's a very good hypothesis that if you have a major pathologic response, then you might not need the six months after.

However, you can flip it and say, these are the really good responders. Maybe they do need the six months after, as opposed to people who have responded less well. So we don't have the data and, you know, it could be a future analysis, we could tell.

BT: Okay. Thank you, lady, gentlemen. It was a very nice discussion, and I hope we're going to help our colleagues.

So thank you very much for listening to us. It was a pleasure being here and see you next time.

Related Videos

Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer

Dr Randy Sweis - University of Chicago, Chicago, USA
Sacituzumab govitecan combination shows promising activity in first line metastatic urothelial cancer ( Dr Randy Sweis - University of Chicago, Chicago, USA )
24 Oct 2026

Bladder cancer updates from the first half of 2026

Prof Alison Birtle, Dr Ignacio Duran, Dr Laura Mertens, Prof Morgan Rouprêt and Dr Patrizia Giannatempo
Bladder cancer updates from the first half of 2026 ( Prof Alison Birtle, Dr Ignacio Duran, Dr Laura Mertens, Prof Morgan Rouprêt and Dr Patrizia Giannatempo )
31 Jul 2026

Part 4: Clinical decision making - Interpretation of next generation sequencing results

Prof Gunhild von Amsberg and Prof Eva Compérat
Part 4: Clinical decision making - Interpretation of next generation sequencing results ( Prof Gunhild von Amsberg and Prof Eva Compérat )
5 May 2026

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands
Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )
18 Mar 2026

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival

Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA
Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival ( Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA )
18 Mar 2026

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada
Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )
18 Mar 2026

Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control

Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA
Cabozantinib shows clinical benefit in refractory GCT with over 40% disease control ( Dr Jennifer King - Indiana University School of Medicine, Indianapolis, USA )
17 Mar 2026

Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

Prof Steffen Rausch - University of Tübingen, Tübingen, Germany
Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC ( Prof Steffen Rausch - University of Tübingen, Tübingen, Germany )
17 Mar 2026

ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA
ctDNA test guides post-surgical immunotherapy for muscle-invasive bladder cancer ( Dr Joaquim Bellmunt - Dana-Farber Cancer Institute, Boston, USA )
20 Oct 2025